{"id":51729,"date":"2026-02-27T19:54:07","date_gmt":"2026-02-27T19:54:07","guid":{"rendered":"https:\/\/bihavadis.com\/?p=51729"},"modified":"2026-02-27T19:54:07","modified_gmt":"2026-02-27T19:54:07","slug":"novo-nordisk-vakfindan-gelecegin-liderlerine-670-bin-euro-destek","status":"publish","type":"post","link":"https:\/\/bihavadis.com\/index.php\/2026\/02\/27\/novo-nordisk-vakfindan-gelecegin-liderlerine-670-bin-euro-destek\/","title":{"rendered":"Novo Nordisk Vakf\u0131\u2019ndan gelece\u011fin liderlerine 670 bin euro destek"},"content":{"rendered":"

Bilim insanlar\u0131na bir ara\u015ft\u0131rma deste\u011fi de Novo Nordisk Vakf\u0131 ve Avrupa Diyabet Ara\u015ft\u0131rmalar\u0131 Vakf\u0131\u2019ndan (EFSD) geldi.<\/p>\n

D\u00fcnyan\u0131n en b\u00fcy\u00fck vak\u0131flar\u0131ndan biri olan ve Novo Nordisk\u2019in \u00e7o\u011funluk hissedar\u0131 konumunda bulunan Novo Nordisk Vakf\u0131, EFSD ile diyabet alan\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7abilecek \u00e7al\u0131\u015fmalar y\u00fcr\u00fcten bilim insanlar\u0131n\u0131 desteklemek i\u00e7in “Gelece\u011fin Liderleri Hibe Program\u0131”<\/em><\/b>n\u0131 (Future Leaders Award Programme) ba\u015flatt\u0131.<\/p>\n

Program, Avrupa\u2019da diyabet alan\u0131nda \u00e7al\u0131\u015fan ba\u015far\u0131l\u0131 gen\u00e7 ara\u015ft\u0131rmac\u0131lar\u0131 destekleyerek gelece\u011fin bilim liderlerini yeti\u015ftirmeyi ama\u00e7l\u0131yor.<\/p>\n

KAR\u0130YER\u0130N KR\u0130T\u0130K D\u00d6NEM\u0130NE UZUN VADEL\u0130 DESTEK<\/strong><\/p>\n

Program\u0131n hedefleri do\u011frultusunda adaylar\u0131n; doktora veya t\u0131p doktoras\u0131 sonras\u0131nda 7\u201312 y\u0131ll\u0131k deneyime sahip akademik kariyerinin orta a\u015famas\u0131nda olan bilim insanlar\u0131 olmalar\u0131 gerekiyor.<\/p>\n

Adaylar\u0131n ayr\u0131ca diyabet ara\u015ft\u0131rma alan\u0131nda ba\u015far\u0131lar\u0131n\u0131 kan\u0131tlam\u0131\u015f olmalar\u0131; yay\u0131nlanm\u0131\u015f makaleleri, alm\u0131\u015f olduklar\u0131 ulusal ve uluslararas\u0131 ara\u015ft\u0131rma fonlar\u0131, y\u00fcr\u00fctt\u00fckleri edit\u00f6rl\u00fck g\u00f6revleri, e\u011fitim ve di\u011fer akademik \u00e7al\u0131\u015fmalar\u0131 ile bu alanda gelece\u011fin lideri olma potansiyeline sahip olduklar\u0131n\u0131 g\u00f6stermeleri bekleniyor.<\/p>\n

Program kapsam\u0131nda be\u015f y\u0131l s\u00fcreyle toplam 5 milyon Danimarka kronu (yakla\u015f\u0131k 670 bin euro) tutar\u0131nda destek, be\u015f e\u015fit taksit halinde sa\u011flanacak. Hibe, \u00f6d\u00fcl kazananlar\u0131n kurumlar\u0131na aktar\u0131lacak ve ara\u015ft\u0131rma giderlerinin yan\u0131 s\u0131ra maa\u015f deste\u011fi ve ekip olu\u015fturma gibi alanlarda kullan\u0131labilecek.<\/p>\n

BA\u015eVURULAR 2 MART 2026\u2019YA KADAR DEVAM EDECEK<\/strong><\/p>\n

Ba\u015fvurular, EFSD\u2019nin \u00e7evrim i\u00e7i ba\u015fvuru sistemi \u00fczerinden 2 Mart 2026 tarihine kadar yap\u0131labilecek. Program\u0131n kapsam\u0131, uygunluk kriterleri ve ba\u015fvuru s\u00fcrecine ili\u015fkin detayl\u0131 bilgiler EFSD ve Novo Nordisk Vakf\u0131\u2019n\u0131n resmi kanallar\u0131 \u00fczerinden payla\u015f\u0131l\u0131yor.<\/p>\n

B\u0130L\u0130ME, TOPLUMA VE \u0130NSANLI\u011eA UZUN VADEL\u0130 YATIRIM<\/strong><\/p>\n

Novo Nordisk\u2019in \u00e7o\u011funluk hissedar\u0131 olan ve ba\u011f\u0131ms\u0131z bir yap\u0131yla faaliyet g\u00f6steren Novo Nordisk Vakf\u0131, insan sa\u011fl\u0131\u011f\u0131, sa\u011fl\u0131k bilimleri ekosistemi ve \u00e7evresel s\u00fcrd\u00fcr\u00fclebilirlik alanlar\u0131nda bilimsel ara\u015ft\u0131rma ve inovasyonu destekliyor. Novo Nordisk\u2019in y\u0131ll\u0131k gelirinin b\u00fcy\u00fck bir k\u0131sm\u0131 her y\u0131l bu vak\u0131fa aktar\u0131l\u0131yor. Vak\u0131f da kurumsal yat\u0131r\u0131mlardan elde etti\u011fi gelirleri bilimsel ve toplumsal faydaya d\u00f6n\u00fc\u015ft\u00fcrmeyi hedefliyor; yaln\u0131zca 2024 y\u0131l\u0131nda bu alanlara sa\u011flad\u0131\u011f\u0131 ba\u011f\u0131\u015flar\u0131n toplam\u0131 1,3 milyar euroyu a\u015ft\u0131.<\/p>\n

“K\u00d6KLER\u0130 B\u0130L\u0130ME DAYANAN B\u0130R VAKIF \u015e\u0130RKET\u0130 YAPISINA SAH\u0130B\u0130Z”<\/strong><\/p>\n

A\u00e7\u0131klamada g\u00f6r\u00fc\u015flerine yer verilen Novo Nordisk T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Bike Ba\u015faklar, konuya ili\u015fkin olarak \u015funlar\u0131 kaydetti:<\/p>\n

Novo Nordisk olarak, k\u00f6kleri bilime dayanan bir vak\u0131f \u015firketi yap\u0131s\u0131na sahibiz. D\u00fcnyan\u0131n en b\u00fcy\u00fck vak\u0131flar\u0131ndan biri olan Novo Nordisk Vakf\u0131 arac\u0131l\u0131\u011f\u0131yla bilime, toplumlara ve insanl\u0131\u011fa fayda sa\u011flayacak projeleri destekliyoruz. Gelece\u011fin Liderleri \u00d6d\u00fcl Program\u0131\u2019n\u0131n T\u00fcrkiye\u2019deki bilim d\u00fcnyas\u0131na ula\u015fmas\u0131 bizim i\u00e7in \u00e7ok k\u0131ymetli. T\u00fcrkiye\u2019deki bilim insanlar\u0131n\u0131n diyabet alan\u0131ndaki yetkinliklerine ve potansiyellerine y\u00fcrekten inan\u0131yoruz. Bu program\u0131n, \u00fclkemizden \u00e7\u0131kacak yeni bilim \u00f6nderlerinin uluslararas\u0131 arenada desteklenmesi i\u00e7in benzersiz bir f\u0131rsat sundu\u011funu d\u00fc\u015f\u00fcn\u00fcyoruz.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk Vakf\u0131 ve Avrupa Diyabet Ara\u015ft\u0131rmalar\u0131 Vakf\u0131 i\u015f birli\u011fi \u00e7er\u00e7evesinde, Avrupa \u00fclkeleri kapsayan Gelece\u011fin Liderleri Hibe Program\u0131 T\u00fcrkiye\u2019deki bilim insanlar\u0131n\u0131n ba\u015fvurusuna a\u00e7\u0131ld\u0131.<\/p>\n","protected":false},"author":1,"featured_media":51730,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[976,42,498,706,2127],"class_list":["post-51729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ekonomi","tag-arastirma","tag-bilim","tag-destek","tag-insan","tag-program"],"_links":{"self":[{"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/posts\/51729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/comments?post=51729"}],"version-history":[{"count":1,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/posts\/51729\/revisions"}],"predecessor-version":[{"id":51732,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/posts\/51729\/revisions\/51732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/media\/51730"}],"wp:attachment":[{"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/media?parent=51729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/categories?post=51729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bihavadis.com\/index.php\/wp-json\/wp\/v2\/tags?post=51729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}